Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Single Dose, Phase Ⅰ Trial to Evaluate the Safety, Tolerability and Prelinminary Efficacy of BD111 in Patients With Herpes Simplex Virus Type I Stromal Keratitis in China

NCT06474416 is registered in ClinicalTrials.gov with Shanghai BDgene Co., Ltd. as lead sponsor.

NCT NCT06474416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06474416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Single Dose, Phase Ⅰ Trial to Evaluate the Safety, Tolerability and Prelinminary Efficacy of BD111 in Patients With Herpes Simplex Virus Type I Stromal Keratitis in China
Lead sponsor
Shanghai BDgene Co., Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 4, 2023
Completion date
March 13, 2026
Enrollment
16 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

herpes simplex virus type i stromal keratitis